Journal: Blood
This publication reviews recent advances in the treatment of follicular lymphoma (FL), highlighting significant improvements in median overall survival. As a result, most patients now die from causes other than FL.
It discusses the approval of novel immunotherapies and targeted agents for relapsed or refractory disease, while emphasizing ongoing challenges such as early progression and transformation to aggressive lymphoma.
The authors anticipate that bispecific antibodies will be integrated earlier and combined with other therapies. They also highlight the development of next-generation bispecifics and CAR T-cell therapies aimed at reducing toxicity and enhancing efficacy.
Emerging technologies like circulating tumor DNA assays may improve personalized treatment decisions and monitoring, potentially replacing imaging in follow-up.
The paper advocates for greater use of quality-of-life assessments to tailor therapy in patients with favorable prognoses.
Finally, it underscores a shift in perspective toward defining and potentially achieving a cure for FL, marking a paradigm shift in disease management.